Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 6/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.33 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.33 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2775935 | 0.88 | GRIA2 (0.48) | GRIA2KMT2AMEN1SRD5A1POLB | |
| SCHEMBL2777706 | 0.82 | GRIA1 (0.31) | GRIA2GRIA1GRIA3GRIA4CA1 | |
| SCHEMBL2773458 | 0.82 | CA12 (0.32) | GRIA2GRIA1GRIA3GRIA4CA1 | |
| SCHEMBL2777517 | 0.82 | GRIA2 (0.48) | GRIA2SRD5A1GRIA1GRIA3GRIA4 | |
| SCHEMBL2179051 | 0.82 | GRIA2 (0.45) | GRIA2CA2 | |
| SCHEMBL2777788 | 0.80 | ALDH1A1 (0.43) | KMT2AMEN1POLBALOX5CA1 | |
| SCHEMBL2777234 | 0.79 | POLB (0.39) | KMT2AMEN1POLBCA1CA2 | |
| SCHEMBL2774604 | 0.78 | GRIA2 (0.43) | GRIA2CA1CA2 | |
| SCHEMBL2777823 | 0.78 | KDM4E (0.43) | KMT2AMEN1ALOX5 | |
| SCHEMBL2776716 | 0.77 | GRIA2 (0.43) | GRIA2SRD5A1GRIA1GRIA3GRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2147915-B1 | New cycloalkylated benzothiadiazine derivatives, method of preparing same and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2010-09-15 | — | — | EP | disclosed |
| US-7741320-B2 | Cycloalkylated benzothiadiazines, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2010-06-22 | — | — | US | disclosed |
| EP-2147915-A1 | New cycloalkylated benzothiadiazine derivatives, method of preparing same and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2010-01-27 | — | — | EP | disclosed |
| US-20100009974-A1 | Cycloalkylated benzothiadiazines, a process for their preparation and pharmaceutical compostions containing them | LES LABORATOIRES SERVIER (FR) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009974-A1 | Cycloalkylated benzothiadiazines, a process for their preparation and pharmaceutical compostions containing them | ACLY, HCAR1, GABRG1 | GRIA2 116/4885KMT2A 1847/4885MEN1 4594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.